| Expression pattern: |
DN |
| Associated gene: |
CCND1, CYCS |
| Associated microRNA: |
hsa-mir-494, hsa-mir-34a |
| Biological function: |
Potential role in RCC development through a predicted ceRNA mechanism; expression was lower in RCC tissues overall but higher in oncocytoma type compared with other RCC types. |
| Molecular mechanism: |
Predicted ceRNA mechanism involving sponging of hsa-mir-494 and hsa-mir-34a to regulate CCND1 and CYCS. |
| Biological pathway or process: |
ceRNA regulation (other); apoptosis (other); cell cycle (other) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
hsa_circ_0006990 had significantly lower expression in RCC patients with a history of kidney disease and higher expression in oncocytoma type compared with other RCC types. |
| Description: |
hsa_circ_0006990 was significantly downregulated in RCC tissues and in ccRCC samples, although it showed higher expression in oncocytoma type relative to other RCC subtypes. The study predicts that it may affect RCC development through a ceRNA mechanism involving hsa-mir-494 and hsa-mir-34a with CCND1 and CYCS. |
| Confidence score: |
0.4685 |